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Abstract
Background: Systemic lupus erythematosus (SLE) is associated with significant impairment of health-related quality
of life (HR-QoL). Recently, meeting a definition of a lupus low disease activity state (LLDAS), analogous to low
disease activity in rheumatoid arthritis, was preliminarily validated as associated with protection from damage
accrual. The LLDAS definition has not been previously evaluated for association with patient-reported outcomes.
The objective of this study was to determine whether LLDAS is associated with better HR-QoL, and examine
predictors of HR-QoL, in a large multiethnic, multinational cohort of patients with SLE.
Methods: HR-QoL was measured using the Medical Outcomes Study 36-item short form health survey (SF-36v2) in
a prospective study of 1422 patients. Disease status was measured using the SLE disease activity index (SLEDAI-2 K),
physician global assessment (PGA) and LLDAS.
Results: Significant differences in SF-36 domain scores were found between patients stratified by ethnic
group, education level and damage score, and with the presence of active musculoskeletal or cutaneous
manifestations. In multiple linear regression analysis, Asian ethnicity (p < 0.001), a higher level of education
(p < 0.001), younger age (p < 0.001) and shorter disease duration (p < 0.01) remained significantly associated
with better physical component scores (PCS). Musculoskeletal disease activity (p < 0.001) was negatively associated with
PCS, and cutaneous activity (p = 0.04) was negatively associated with mental component scores (MCS). Patients in
LLDAS had better PCS (p < 0.001) and MCS (p < 0.001) scores and significantly better scores in multiple individual SF-36
domain scores. Disease damage was associated with worse PCS (p < 0.001), but not MCS scores.
Conclusions: Ethnicity, education, disease damage and specific organ involvement impacts HR-QoL in SLE. Attainment
of LLDAS is associated with better HR-QoL.
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Background
Systemic lupus erythematosus (SLE) is a chronic multi-
system autoimmune disease resulting in significant
morbidity and reduced quality of life. With the im-
provement in overall survival of patients with SLE com-
pared to historical outcomes [1], a growing number of
young adults face the burden of chronic disease, which
includes not only the activity of the disease itself, the
adverse effects of treatment and the complications such
as organ damage [2], but also the impact of disease on
physical function, quality of life and employment. Health-
related quality of life (HR-QoL) is a multi-dimensional
construct that evaluates different health perceptions and
self-reported functional status, and is often included as a
key patient-reported outcome (PRO) in studies of chronic
disease.
Both generic and disease-specific instruments have
been developed to facilitate measurement of PROs,
resulting in an increase in the number of studies asses-
sing HR-QoL in SLE [3–6]. PROs are increasingly recog-
nized as an integral part of assessment in clinical trials
and in routine practice [7, 8], as they measure domains
not captured by physician-assigned disease activity
scores. Patients with SLE perform poorly on HR-QoL
measures when compared to the general population [9],
especially those with concomitant fibromyalgia [10] or
fatigue [6, 11]. The effects of SLE on HR-QoL are com-
parable to other chronic diseases such as chronic heart
failure, coronary artery disease, end-stage airways
disease, human immunodeficiency virus and rheumatoid
arthritis [12–14]. In addition, it has been reported that
patients with SLE feel misunderstood by their families,
the community and even the specialists treating them
[15]. Consequently, patients feel that their quality of life
needs are not being met by treating teams [16, 17].
As recently highlighted, measures of a treatment out-
come status for use in clinical trials, or in treat-to-target
strategy studies, have been lacking in SLE [18, 19].
Definitions of remission may be too stringent for use
in routine practice or clinical trials [20], highlighting
the need for a definition of low disease activity [18,
19]. Recently, we reported the definition and prelim-
inary validation of a lupus low disease activity state
(LLDAS), combining disease activity and treatment
domains, attainment of which was shown in a longi-
tudinal cohort study to be protective against damage
accrual [21]. For such a measure to have value in
clinical practice and clinical trials, it should be associ-
ated not only with physician-applied measures of
disease activity and damage, but also with PROs. The
objectives of this study were to determine whether
LLDAS is associated with better HR-QoL, and to
determine other predictors of HR-QoL in a large mul-
tiethnic multinational cohort of patients with SLE.
Methods
Study population
Ten centers from seven countries took part in this study.
Patients over the age of 18 years, who fulfilled the classi-
fication criteria for SLE (either the 1997 American
College of Rheumatology (ACR) criteria [22] or the 2012
Systemic Lupus International Collaborating Clinics
(SLICC) criteria [23]) were eligible. The study centers
are members of the Asia Pacific Lupus Collaboration
(APLC), involved in a multicenter prospective longitu-
dinal study of SLE outcomes; data reported here repre-
sent all patients with complete data acquisition from the
enrollment visit. Data collection took place between
May 2013 and August 2015, during the routine ambula-
tory care of each patient, using either a standardized
paper or electronic case report form.
Measurement of HR-QoL
HR-QoL was measured using the Medical Outcomes
Study 36-item short form health survey (SF-36v2)
[24], a generic instrument validated in a number of
SLE observational cohorts and clinical trials, and vali-
dated in each of the languages used by patients in this
study [3, 4, 10, 13, 25, 26]. The SF-36 comprises eight
domains including physical function (PF), role physical
(RP), bodily pain (BP), general health (GH), vitality
(VT), social function (SF), role emotional (RE) and
mental health (MH), and two summary scores defined
as the physical component score (PCS) and mental
component score (MCS). The individual domain
scores are expressed on a scale of 0 to 100, and the
component summary scores are standardized around a
USA normal population mean of 50, with higher
scores representing better HR-QoL.
Other variables
Demographic information, disease characteristics and
data on clinical variables were collected from each
patient at the study visit date. Demographic variables
included gender, ethnicity (self-reported based on the
Australian Standard Classification of Cultural and Ethnic
Groups [27]), date of birth, year of SLE diagnosis, smok-
ing status, and highest-attained education level. Disease
manifestations were determined from the ACR and
SLICC classification criteria [22, 23], recorded at study
entry on an ever-present basis. Current doses of gluco-
corticoids and immunosuppressive medications were
recorded for each patient. Disease activity was measured
using the SLE disease activity index (SLEDAI-2 K) [28],
with specific organ system activity derived from compo-
nents of the SLEDAI-2 K.
Additional disease status measures included a phys-
ician global assessment (PGA) of disease activity on a
scale of 0 to 3 [29], and fulfillment of the criteria for
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LLDAS [21]. The operational definition of LLDAS is ful-
filled when all of the following criteria are met: (1)
SLEDAI-2 K ≤4, with no activity in major organ systems
(renal, central nervous system (CNS), cardiopulmonary,
vasculitis or fever) and no hemolytic anemia or gastro-
intestinal activity; (2) no new features of lupus disease
activity compared to the previous assessment; (3) a
Safety of Estrogens in Lupus Erythematosus National
Assessment (SELENA)-SLEDAI PGA (scale 0–3) ≤1; (4)
a current prednisolone (or equivalent) dose ≤7.5 mg
daily and (5) well-tolerated standard maintenance doses
of immunosuppressive drugs and approved biologic
agents, excluding investigational drugs. Disease flares
compared to the previous visit were measured using the
SELENA-SLE flare index (SFI) [29]. Irreversible disease
damage was measured using the SLICC damage index
(SLICC-DI) [30].
Data analysis
Pooled cross-sectional data from all centers were ana-
lyzed using STATA v13 (StataCorp, College Station, TX,
USA). Individual domain and component summary
scores are expressed as median and interquartile range,
as the data were not normally distributed. To allow for
linear regression analysis, domain and summary scores
were log-transformed prior to inclusion into models in
order to fulfill the assumption of a normal distribution.
The exponentiated regression coefficients (coeff ) are re-
ported in results for ease of clinical interpretation. This
represents (coeff-1)*100% increase or decrease in PCS or
MCS scores for every one-unit change in continuous
independent variables or a change in category for
categorical independent variables.
Variables with a p value ≤0.1 in simple linear regression
analysis were checked for multicollinearity prior to inclu-
sion into backward stepwise multiple linear regression
models for PCS and MCS scores. LLDAS is a composite
measure comprising the SLEDAI, PGA, flare index, pred-
nisolone dose and medication use. In addition to assessing
the relationship between LLDAS and HR-QoL (model 1),
a separate multiple linear regression model was used to
ascertain to what degree individual LLDAS components
contributed to this relationship (model 2). A third model
of the LLDAS components was also tested, but using
organ system activity rather than the total SLEDAI-2 K
score (model 3). Model adequacy was evaluated using
adjusted R2, residual and normality plots.
Results
Demographic and disease characteristics
A total of 1422 patients were studied. The majority of
patients were female (93%), with a mean (±SD) age at
diagnosis of 31.2 (±12.2) years and mean (±SD) disease
duration of 9.2 (±7.7) years. Caucasians formed 8% of
the sample, with the rest of the patients representing
Asian ethnicities native to the region (Table 1). Other
demographic characteristics are also shown in Table 1.
More than half of patients had a history of malar rash,
arthritis, hematologic or immunologic manifestations,
and 46% had a history of renal disease (Additional file 1:
Table S1). The median score in the SLEDAI-2 K was 4
(IQR 2–6). There were 369 patients (26%) with active
renal disease, 273 (19%) with cutaneous activity and 119
(8.4%) with musculoskeletal activity; 593 patients (42%)
fulfilled criteria for LLDAS (Table 1). The median
SLICC-DI score was 0 (IQR 0–1), with 498 patients
(35%) having some damage (SLICC-DI >0).
Individual domain and component summary scores of
the SF-36v2 are presented in Table 2. Overall, domains
with the highest (best) median, IQR (25th–75th) scores
included physical functioning (85, 65–95), role physical
(75, 50–100), role emotional (83.3, 58.3–100), and social
functioning (75, 50–100). The lowest (worst) medians
were observed in vitality (62.5, 50–75) and general
health (57, 40–72).
Determinants of HR-QoL
Significant differences in the scores for individual SF-36
domains were seen in relation to ethnicity, education,
damage and active disease manifestations. Patients of
Asian ethnicity had higher (better) scores in domains in-
cluding role physical, bodily pain, general health, vitality,
and social function (Fig. 1a; Additional file 1: Table S2).
Higher education was also associated with higher do-
main scores, while the presence of damage, or active
musculoskeletal or cutaneous manifestations, were asso-
ciated with lower (worse) scores across multiple domains
(Fig. 1b, c, d; Additional file 1: Table S2). The presence
or absence of renal activity did not significantly impact
on SF-36 domain scores.
Higher disease activity as measured by the SLEDAI-2 K
and PGA, and higher prednisolone dose, were each signifi-
cantly associated with lower (worse) PCS and MCS scores
in simple linear regression analysis (Table 3). With regard
to organ domains of disease activity as measured using
SLEDAI-2 K, patients with active musculoskeletal mani-
festations had significantly poorer PCS scores (coeff 0.89,
p < 0.001), whereas patients with cutaneous manifestations
had significantly worse MCS (coeff 0.94, p < 0.001). Nei-
ther PCS nor MCS scores were significantly different
between patients with or without active renal disease. The
presence of damage was associated with significantly
worse PCS scores, but no differences in MCS scores were
observed. Older age at diagnosis (coeff 0.997, p < 0.001)
and longer disease duration (coeff 0.997, p < 0.001) were
also associated with poorer PCS but not MCS scores.
We also analyzed the effect of country of study site
and education level as variables. Australian patients
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recorded the worst PCS scores (43.5, 36.1–52.3), and
Chinese patients the worst MCS scores (44.9, 38.5–55.8).
In simple linear regression analysis, Asian patients had
significantly better PCS scores than their Caucasian
counterparts (coeff 1.22, p < 0.001) regardless of the
country of residence. Both PCS and MCS scores were sig-
nificantly higher in patients with higher levels of educa-
tion (Table 3). In backward stepwise multiple linear
regression, multiple variables remained significantly
associated with PCS (Table 4). The presence of dam-
age remained negatively associated with PCS scores
(p < 0.001). In contrast, shorter disease duration,
younger age at diagnosis, Asian ethnicity, and higher
level of education remained significantly positively
associated with PCS. Patients with tertiary education
(p < 0.01) had better MCS scores. The model set-up
and properties are shown in Table 4.
Association between LLDAS or disease activity measures
and HR-QoL
Patients who fulfilled criteria for LLDAS had significantly
higher scores in individual SF-36 domains including role
Table 1 Patient demographics and disease characteristics
Number (%) or mean (SD) or
median (IQR: 25th–75th)
Country, n (%)
Australia 217 (15%)
China 222 (16%)
Indonesia 98 (7%)
Philippines 124 (9%)
Singapore 219 (15%)
Taiwan 294 (21%)
Thailand 250 (18%)
Ethnicity, n (%)
Caucasian 116 (8%)
Chinese 699 (49%)
Filipino 132 (9%)
Indonesian 101 (7%)
Thai 254 (18%)
Malay 37 (3%)
Vietnamese/Cambodian 22 (2%)
Indian/Sri Lankan 35 (2%)
Othera 28 (2%)
Gender, n (%)
Female 1329 (93%)
Highest attained education levelb
Primary 241 (17%)
Secondary 548 (38%)
Tertiary 607 (42%)
Age at diagnosis (years) 31.1 (12.2)
Disease duration (years) 9.2 (7.7)
SLICC-DI score 0 (0–1)
Damage presentc 498 (35%)
PGA at enrollment 0.5 (0.2–1)
Mild flare 170 (12%)
Severe flare 100 (7%)
SLEDAI-2 K 4 (2–6)
Current CNS activityd 9 (0.6%)
Current vasculitisd 23 (1.6%)
Current renal activityd 369 (25.9%)
Current musculoskeletal activityd 119 (8.4%)
Current cutaneous activityd 273 (19.2%)
Current serositisd 12 (0.8%)
Lupus low disease activity state (LLDAS) 593 (42%)
Table 1 Patient demographics and disease characteristics
(Continued)
Number (%) of patients taking
prednisoloneg
1167 (82%)
Taking immunosuppressante 762 (53.5%)
Taking antimalarialf 1044 (73.3%)
aOther includes Hispanic, African, other South-East Asian, Pacific Islander and
mixed ethnicity. bPercent present shown in table, percent absent and missing
not shown in table. cSLICC-DI >0. dActive based on non-zero SLEDAI-2 K scores in
organ domains as indicated. eEither methotrexate, azathioprine, mycophenolate,
leflunomide, cyclosporine, cyclophosphamide (in the last 6 months), rituximab
(in the last 6 months) and/or belimumab (in the last 6 months). fEither
hydroxychloroquine or chloroquine. Abbreviations: SLE systemic lupus
erythematosus, SLEDAI SLE disease activity index, SLICC Systemic Lupus
International Collaborating Clinics, DI damage index, PGA physician global
assessment, CNS central nervous system, CVA cerebrovascular accident
gMean dose (SD) 12 mg (13.7)
Table 2 Short form-36 domain and component summary
scores
Median (IQR: 25th–75th)
Physical functioning 85 (65–95)
Role physical 75 (50–100)
Bodily pain 74 (51–84)
General health 57 (40–72)
Vitality 62.5 (50–75)
Social functioning 75 (50–100)
Role emotional 83.3 (58.3–100)
Mental health 70 (56–80)
Physical component summary score 49.73 (42.74–54.67)
Mental component summary score 48.34 (40.7–53.32)
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physical, bodily pain, general health, vitality, social func-
tion, role emotional and mental health (Fig. 2). The only
domain not significantly higher (better) in patients who
met the criteria for LLDAS was physical function. Patients
in LLDAS also had higher PCS and MCS scores (Table 3).
After backward stepwise multiple linear regression adjust-
ment for other variables, patients in LLDAS retained
higher PCS scores (p < 0.001) and MCS scores (p < 0.001)
(model 1, Table 4). These findings support the utility of
LLDAS and its association with HR-QoL. Analysis of
LLDAS individual components in multiple linear regression
(model 2, Table 4) showed that a higher SLEDAI-2 K score
(p = 0.05), PGA (p < 0.001) and prednisolone dose (p = 0.01)
remained negatively associated with PCS scores, whereas
disease flares did not have a significant association.
Only the PGA (p = 0.02) remained significantly nega-
tively associated with MCS scores. Assessing individual
organ activity instead of total SLEDAI-2 K score
(model 3, Table 4) showed after adjustment that mus-
culoskeletal activity (p < 0.001) remained negatively
associated with PCS scores, and active cutaneous
disease (p = 0.04) remained negatively associated with
MCS scores.
Discussion
The ability to define an achievable treatment goal that is
predictive of improved outcomes is essential for the
implementation of treat-to-target strategies in SLE, and
potentially has utility in the analysis of trials of current
and novel therapies [19, 31]. Recently, the need to define
Fig. 1 Radar charts comparing short form-36 (SF-36) domain median scores between Asian and Caucasian ethnicity (a), primary, secondary and tertiary
education levels (b), presence (Systemic Lupus International Collaborating Clinics damage index (SLICC)-damage index (DI) >0) and absence (SLICC-DI = 0)
of disease damage (c) and presence and absence of musculoskeletal (MSK) activity - either arthritis or myositis on the systemic lupus erythematosus disease
activity index-2 K (SLEDAI-2 K) (d). Each spoke on the radar chart represents an SF-36 domain on a scale of 0–100, with higher scores representing better
health-related quality of life. The domains are physical function (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social function (SF),
role emotional (RE) and mental health (MH). *p< 0.001; #p< 0.01 using the two-sample Wilcoxon rank-sum (Mann-Whitney) test or Kruskal-Wallis test
as appropriate
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treatment goals for SLE has received increased attention
[20], consequent upon which we reported the definition
of a low disease activity treatment outcome state,
LLDAS [21]. When disease activity and treatment do-
mains are combined, both of which have been shown to
contribute to an adverse long-term outcome in SLE, sus-
tained attainment of LLDAS is associated with protection
from accrual of damage over time, as measured using the
SLICC-DI, in retrospective analysis of prospectively
collected data [21]. Whether LLDAS is associated with
measures of HR-QoL has not previously been assessed.
An important finding in the present study is the asso-
ciation between LLDAS and better HR-QoL, even after
adjustment for other variables that were associated with
HR-QoL. The LLDAS definition represents a composite
tool with which patients with clinically diverse pheno-
types can be stratified in a binary fashion, as either
meeting criteria for LLDAS or not. This “reductionistic”
approach takes advantage of the fact that the heterogen-
eity of disease expression in active SLE is, by definition,
lessened as the disease activity lessens [18]. By combin-
ing different measures of clinical activity, and those of
medication burden, the LLDAS is an encompassing
measure of the overall clinical state of the patient, and
emerging data confirm that the domains of LLDAS con-
tribute independently to the stringency of the measure
[32]. This means that LLDAS, rather than simply repre-
senting a description of mild disease, represents a com-
posite treatment target state. Non-attainment of LLDAS
could therefore reflect flare, refractory disease or insuffi-
cient treatment intensity, just as is the case with low
disease activity definitions in RA. Given that improve-
ment in HR-QoL is recognized as an important outcome
measure in clinical trials [3, 8], the association between
LLDAS and better SF-36 scores further supports its
utility as a treatment target. Prospective studies showing
that attainment of LLDAS is associated with improve-
ments in HR-QoL over time are required, and are in
progress.
In order to scrutinize the effects of the LLDAS com-
ponents on HR-QoL, we utilized separate multiple linear
regression models. SLEDAI-2 K, PGA and prednisolone
dose (potentially a surrogate for activity) were each sig-
nificantly and negatively associated with PCS scores, but
only the PGA was negatively associated with MCS
scores. Interestingly, disease flares as measured by the
SFI were not significantly associated with either PCS or
MCS scores. Of note, due to the cross-sectional nature
of the analyses in this study, the SFI was used as a surro-
gate for the third criterion of LLDAS, which is that there
must be no new features of lupus disease activity com-
pared to the previous assessment [21]. It is possible that
with longitudinal analysis, this LLDAS criterion may be
significantly associated with HR-QoL.
The relationship between disease activity and HR-QoL
in SLE remains controversial in the published literature
[12, 25, 33–35], likely due to a combination of varying
study designs, an inherently heterogeneous disease, dif-
ferent measures of activity and fluctuating disease states.
Our study is the first to analyze HR-QoL in relation to
individual organ system activity based on the SLEDAI.
We observed a negative association between active mus-
culoskeletal disease and poorer PCS, and between active
cutaneous disease and poorer MCS scores. We consider
that it makes clinical sense that active joint and muscle
disease affects physical function, while cutaneous disease
influences mental wellbeing; young women with SLE
who comprise the majority of patients are known to suf-
fer from poor body image [36]. An effect of renal activity
on HR-QoL has been described by Appenzeller et al.,
who reported that patients with active renal disease had
slightly poorer physical function, albeit with wide confi-
dence intervals [37]. In contrast we found no significant
association between active renal disease and any domains
of the SF-36. Some organ involvement, such as lupus
nephritis, may be inherently clinically silent in terms of
HR-QoL, despite reflecting a serious threat to health.
Although undertaken in order to evaluate the associ-
ation between LLDAS and HR-QoL, this is one of the
largest studies to date of HR-QoL in patients with SLE,
and as such it affords the opportunity to investigate
other factors associated with HR-QoL in SLE. Patient
characteristics, such as ethnicity, have previously been
shown to be associated with various aspects of disease
burden in SLE [38, 39], with Caucasian patients having
lower disease activity but reporting poorer HR-QoL
compared to their non-Caucasian counterparts [35, 40].
Studies from individual countries within the Asia Pacific
region report poorer HR-QoL in patients with SLE com-
pared to national averages [33], and negative associations
with poorer socioeconomic status [26]. However, to date,
between-country comparisons have been lacking.
We have demonstrated important regional and
ethnic differences in HR-QoL. In our study, compared
to Caucasians, patients of Asian ethnicity reported
better PCS, even when adjusted for other variables, but
no significant differences in MCS scores. Similar findings
have been reported in different ethnic groups in Canada
and the USA, with white ethnicity associated with poorer
physical, but not mental function [4, 35]. The SF-36 has
been cross-culturally validated to allow global compari-
sons, but it is unlikely that it is sensitive to all cultural and
ethnic nuances. The significant difference in PCS and
MCS scores between countries in our cohort, even when
adjusted for ethnicity and disease factors, further high-
lights the importance of cultural differences in perception
of the impact of disease and patients’ coping strategies,
which have been suggested to be just as important as
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disease states in determining HR-QoL in SLE [41]. The
ability to cope better with illness was potentially reflected
in the association between higher education and better
summary scores, a finding supported by previous studies
[4, 33]. However, this may also be indicative of patients
with higher levels of education being employed in less
manually labor-intensive jobs, therefore with potentially a
less noticeable impact on physical function.
Studies assessing the association between organ dam-
age and HR-QoL have reported discrepant results. We
identified significant association between greater damage
and PCS scores, but not MCS scores, which is also seen
Table 3 Association of patient and disease characteristics with short form-36 component summary scores in simple linear regression
Variable Physical component summary Mental component summary
Coeff* p 95% CI Coeff* p 95% CI
Country
Australia reference - - 1.06 0.01 1.01–1.10
China 1.14 <0.001 1.10–1.18 reference
Indonesia 1.11 <0.001 1.06–1.16 1.06 0.04 1.01–1.12
Philippines 1.23 <0.001 1.18–1.28 1.20 <0.001 1.14–1.26
Singapore 1.14 <0.001 1.10–1.18 1.13 <0.001 1.08–1.18
Taiwan 1.14 <0.001 1.11–1.18 1.05 0.01 1.01–1.10
Thailand 1.12 <0.001 1.09–1.16 1.04 0.10 0.99–1.08
Ethnicity
Caucasian reference - - reference - -
Asian 1.22 <0.001 1.18–1.26 1.03 0.19 0.99–1.08
Gender
Female reference - - reference - -
Male 1.02 0.42 0.98–1.06 0.99 0.95 0.95–1.05
Education
Primary reference - - reference - -
Secondary 1.05 0.001 1.02–1.08 1.01 0.47 0.98–1.05
Tertiary 1.09 <0.001 1.06–1.13 1.06 0.002 1.02–1.09
Age at diagnosis (years) 0.997 <0.001 0.996–0.998 1.00 0.76 0.998–1.001
Disease duration (years) 0.997 <0.001 0.996–0.999 1.00 0.07 0.999–1.003
SLEDAI score 0.994 <0.001 0.992–0.996 0.997 0.03 0.994–0.999
Current organ activity
CNS 0.82 0.003 0.73–0.93 0.93 0.32 0.79–1.08
Renal 0.98 0.12 0.96–1.00 0.99 0.37 0.96–1.02
MSK 0.89 <0.001 0.86–0.93 0.95 0.03 0.91–0.99
Vasculitis 0.90 0.02 0.83–0.98 0.96 0.46 0.88–1.06
Cutaneous 0.97 0.02 0.94–0.99 0.94 0.001 0.92–0.98
Serositis 0.86 0.01 0.77–0.96 1.04 0.58 0.91–1.18
PGA (0–3) 0.94 <0.001 0.93–0.96 0.94 <0.001 0.93–0.96
Mild flare 0.95 0.002 0.92–0.98 0.98 0.25 0.94–1.02
Severe flare 0.89 <0.001 0.86–0.93 0.95 0.03 0.90–0.99
Prednisolone dose (mg) 0.998 <0.001 0.997–0.999 0.998 <0.001 0.997–0.999
LLDAS 1.04 <0.001 1.02–1.06 1.06 <0.001 1.04–1.09
SLICC-DI score 0.95 <0.001 0.94–0.96 0.99 0.43 0.99–1.01
*Coefficient (Coeff) is based on the log-linear model and back-transformed using the exponential function. This represents (coeff-1)*100% increase/decrease in
physical component summary or mental component summary scores for change in category (categorical variables), or (coeff-1)*100% change per one unit (continuous
variables). Abbreviations: SLEDAI systemic lupus erythematosus disease activity index, MSK musculoskeletal, PGA physician global assessment, LLDAS lupus low disease
activity state, SLICC Systemic Lupus International Collaborating Clinics, DI damage index, CNS central nervous system
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Table 4 Backward stepwise multiple linear regression for physical component summary (PCS) and mental component summary
(MCS)
Model Variable Model 1 Model 2 Model 3
Common
variables
PCS MCS PCS MCS PCS MCS
Coeff p Coeff p Coeff p Coeff p Coeff p Coeff p
Model 1 Country
Australia reference - 1.05 0.10 reference - 1.04 0.19 reference - 1.06 0.08
China 1.04 0.09 reference - 1.06 0.02 reference - 1.05 0.04 reference -
Indonesia 1.01 0.73 1.06 0.04 1.02 0.40 1.07 0.03 1.02 0.45 1.07 0.02
Philippines 1.10 <0.001 1.17 <0.001 1.12 <0.001 1.18 <0.001 1.12 <0.001 1.19 <0.001
Singapore 1.08 <0.01 1.12 <0.001 1.09 <0.001 1.12 <0.001 1.09 <0.001 1.13 <0.001
Taiwan 1.06 0.01 1.04 0.08 1.07 <0.01 1.03 0.15 1.06 0.01 1.03 0.14
Thailand 1.04 0.11 1.02 0.33 1.05 0.06 1.02 0.39 1.04 0.12 1.02 0.30
Ethnicity
Caucasian reference - reference - reference - reference - reference - reference -
Asian 1.10 <0.001 1.02 0.50 1.10 <0.001 1.02 0.62 1.10 <0.001 1.02 0.53
Education
Primary reference - reference - reference - reference - reference - reference -
Secondary 1.03 0.03 1.03 0.12 1.03 0.03 1.03 0.16 1.03 0.04 1.03 0.13
Tertiary 1.05 0.002 1.06 <0.01 1.05 0.001 1.06 <0.01 1.05 0.001 1.06 <0.01
Age at diagnosis
(years)
0.997 <0.001 1.00 0.39 0.997 <0.001 1.00 0.39 0.997 <0.001 1.00 0.37
Disease duration
(years)
0.998 0.05 1.00 0.06 0.998 <0.01 1.00 0.08 0.998 <0.01 1.00 0.10
SLICC-DI score 0.96 <0.001 0.99 0.13 0.96 <0.001 0.99 0.21 0.97 <0.001 0.99 0.15
LLDAS 1.06 <0.001 1.05 <0.001 - - - - - - - -
Model 2 SLEDAI score - - - - 0.997 0.05 1.00 0.35 - - - -
PGA (0–3) - - - - 0.95 <0.001 0.97 0.02 - - - -
Mild flare - - - - 0.98 0.26 0.98 0.25 - - - -
Severe flare - - - - 0.97 0.11 0.97 0.33 - - - -
Prednisolone (mg) - - - - 0.998 0.01 0.999 0.13 - - - -
Model 3 Current organ activity
Renal - - - - - - - - 1.00 0.43 1.02 0.29
MSK - - - - - - - - 0.93 <0.001 0.99 0.55
Vasculitis - - - - - - - - 0.99 0.84 1.02 0.74
Cutaneous - - - - - - - - 0.95 0.70 0.94 0.04
Serositis - - - - - - - - 0.96 0.34 1.04 0.49
PGA (0–3) - - - - - - - - 0.99 <0.001 0.97 0.03
Mild flare - - - - - - - - 0.99 0.59 0.99 0.58
Severe flare - - - - - - - - 0.96 0.04 0.98 0.36
Prednisolone (mg) - - - - - - - - 0.998 <0.01 0.999 0.19
Variables with p values ≤0.1 in simple linear regression analysis were checked for multicollinearity prior to inclusion in the models. To account for different
measures of disease activity and disease state that were collinear and to ascertain which of the LLDAS criteria contributed to the relationship with health-related
quality of life, three models were used: Model 1 - disease state measured as lupus low disease activity state (LLDAS); Model 2 - breakdown of LLDAS into its
individual components/criteria representing measures of disease activity – the systemic lupus erythematosus disease activity index (SLEDAI) score, physician global
assessment (PGA), flare index and prednisolone dose; Model 3 - breakdown of SLEDAI score by current organ activity, and PGA, flare index and prednisolone dose.
Common independent variables used in all three models are at the top of the table and include: country, ethnicity, education, age at diagnosis, disease duration and
Systemic Lupus International Collaborating Clinics (SLICC)-damage index (DI) score. Coefficient (Coeff) is based on log-linear model and back-transformed using the
exponential function. This represents (coeff-1)*100% increase/decrease in PCS or MCS scores for change in category (categorical variables), or (coeff-1)*100% change per
one unit (continuous variables). Abbreviations: CNS (cntral nervous system, MSK musculoskeletal. P values in italics are significant
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in the ethnically diverse LUMINA cohort [4]. Similarly,
in a longitudinal study of Chinese patients from Hong
Kong, Mok et al., showed that accrual of new damage
predicted a decline in SF-36 scores [33]. In contrast, in a
predominantly Caucasian population with low damage
accrual over 8 years, no disease features were associated
with decline in physical functioning except for the pres-
ence of fibromyalgia [35].
The lack of measurements to identify fibromyalgia and
other comorbidities is one of the limitations of this
study, as pain and fatigue have been shown to independ-
ently influence HR-QoL in patients with SLE [6, 10, 11].
Two domains of the SF-36, bodily pain and vitality, are
potential surrogate measures for pain and fatigue re-
spectively. Patients in LLDAS had significantly higher
(better) scores in both of these domains, with the infer-
ence that LLDAS may be associated with a reduction in
pain and fatigue. A disease-specific HR-QoL tool could
further address the additional issues pertinent to patients
with SLE and assess the effect of LLDAS on these; how-
ever, the currently available disease-specific instruments
have not been validated in all the spoken languages of
this multicultural cohort of patients.
Additionally, clear evidence of superiority is lacking
among the multiple disease-specific HR-QoL tools [5].
The cross-sectional nature of the analyses does not allow
the assessment of changes in HR-QoL with fluctuating
disease states. However, given that the SF-36 is designed
to capture HR-QoL in the preceding 4 weeks, the same
time frame as the evaluation of disease activity, it should
be relevant to disease activity measures captured at the
same time. A longitudinal study is underway, which will
enable analysis of the association between LLDAS and
transitions in HR-QoL measured by the SF36. Assess-
ment of the effect of LLDAS on other PRO measures,
such as patient assessment of disease activity, could form
the basis of future validation studies.
Conclusions
In summary, we have shown for the first time that
LLDAS is associated with better HR-QoL. This supports
the validity of this definition of treatment outcome state
for potential use in clinical practice, treat-to-target stud-
ies and clinical trials. This conclusion would be further
supported by longitudinal studies, of which at least one
is underway. In addition, we have described important
ethnic, socioeconomic and disease-specific associations
with HR-QoL in one of the largest multiethnic SLE co-
horts ever studied. Attention to reversible or preventable
precipitants of poor HR-QoL should be included in the
management of SLE.
Additional file
Additional file 1: Table S1. Disease manifestations ever present. Table S2.
Comparison of SF-36 domain scores by patient and disease characteristics
(DOCX 19 kb)
Fig. 2 Radar chart comparing short form-36 (SF-36) domain scores between patients in lupus low disease activity state (LLDAS) and those not in
LLDAS. Each spoke on the radar chart represents an SF-36 domain on a scale of 0–100, with higher scores representing better health-related quality of
life. The domains are: physical function (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social function (SF), role emotional (RE),
and mental health (MH). *p < 0.001; #p < 0.01 using the two-sample Wilcoxon rank-sum (Mann-Whitney) test
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